IP8 Depression Therapeutics Practice Test

Levomilnacipran hits norepinephrine reuptake transporters more potently than it does other targets, so it acts as a stronger inhibitor of NE reuptake. This means it can produce greater NE-related effects in the synapse. However, that increased NE inhibition does not translate into higher antidepressant efficacy in clinical trials compared with other SNRIs or milnacipran itself. So the best description is that it is a stronger NE reuptake inhibitor, but it does not have greater overall efficacy.